Loading
For each drug target, show how many programmes have been tried against it and how many failed, so new teams know what they are up against.
Target prioritisation platforms (Open Targets) weight positive evidence. A complementary index that aggregates discontinued programmes, failed trials and deposited negative preclinical results per target and indication, with reasons where known, would give a Bayesian prior: a target with eight failed programmes and no success should require a stronger hypothesis than one never tried. Publicly available pipeline data makes a first version feasible now.
Shares A registry for preclinical experiments that did not work, Failures are hidden.
Shares A registry for preclinical experiments that did not work, Failures are hidden.
Shares A machine-readable taxonomy of why cancer drugs fail, Failures are hidden.
Shares A registry for preclinical experiments that did not work, Failures are hidden.
Shares A registry for preclinical experiments that did not work, Failures are hidden.
Shares A machine-readable taxonomy of why cancer drugs fail, Failures are hidden.
Shares A registry for preclinical experiments that did not work, Failures are hidden.
Shares A machine-readable taxonomy of why cancer drugs fail, Failures are hidden.